

Article

Synthesis, Antitumor and Antibacterial Studies of New Shortened Analogues of (KLAKLAK)₂-NH₂ and Their Conjugates Containing Unnatural Amino Acids

Sirine Jaber ¹, Ivan Iliev ², Tsvetelina Angelova ¹, Veronica Nemska ¹, Inna Sulikovska ², Emilia Naydenova ^{1,*}, Nelly Georgieva ¹, Ivan Givechev ^{1,3}, Ivo Grabchev ⁴ and Dancho Danalev ^{1,*}

¹ University of Chemical Technology and Metallurgy, 8 Kliment Ohridski blvd., 1756 Sofia, Bulgaria; Jaber-Sirine@hotmail.com (S.J.); tsvetelina_angelova@abv.bg (T.A.); vnemska@uctm.edu (V.N.); neli@uctm.edu (N.G.); ivangivechev@gmail.com (I.G.)

² Institute of Experimental Morphology, Pathology and Anthropology with Museum, Bulgarian Academy of Sciences, Acad. G. Bonchev str., bl. 25, 1113 Sofia, Bulgaria; taparsky@abv.bg (I.I.); inna_sulikovska@ukr.net (I.S.)

³ Testing Center Global Test Ltd., 31 Krushovski vrah Street, 1618 Sofia, Bulgaria

⁴ Department of Chemistry and Biochemistry, Physiology and Pathophysiology, Sofia University "St. Kliment Ohridski", 1504 Sofia, Bulgaria; i.grabchev@chem.uni-sofia.bg

* Correspondence: emilia@uctm.edu (E.N.); ddanalev@uctm.edu (D.D.); Tel.: +359-2-8163425 (E.N.); +359-2-8163310 (D.D.)



Citation: Jaber, S.; Iliev, I.; Angelova, T.; Nemska, V.; Sulikovska, I.; Naydenova, E.; Georgieva, N.; Givechev, I.; Grabchev, I.; Danalev, D. Synthesis, Antitumor and Antibacterial Studies of New Shortened Analogues of (KLAKLAK)₂-NH₂ and Their Conjugates Containing Unnatural Amino Acids. *Molecules* **2021**, *26*, 898. <https://doi.org/10.3390/molecules26040898>

Academic Editor: Manoj K. Pandey

Received: 12 January 2021

Accepted: 5 February 2021

Published: 8 February 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: (1) Background: (KLAKLAK)₂ is a representative of the antimicrobial peptide group which also shows good anticancer properties. (2) Methods: Herein, we report synthesis using SPPS and characterization by HPLC/MS of a series of shortened analogues of (KLAKLAK)₂. They contain single sequence KLAKLAK as C-terminal amides. In addition, substitution of some natural amino acids with unnatural β-Ala and nor-Leu is realized. In addition, these structures are conjugated with second pharmacophore with well proven anticancer properties 1,8-naphthalimide or caffeic acid. Cytotoxicity, antiproliferative effect and antimicrobial activity of newly synthesized structures were studied. (3) Results: The obtained experimental results reveal significant selective index for substances with common chemical structure KLβAKLβAK-NH₂. The antibacterial properties of newly synthesized analogues at two different concentrations 10 μM and 20 μM, were tested against Gram-negative microorganisms *Escherichia coli* K12 407. Only two of the studied compounds KLAKLAK-NH₂ and the one conjugated with second pharmacophore 1,8-naphthalimide and unnatural amino acid nor-Leu showed moderate activity against tested strains at concentration of 20 μM. (4) Conclusions: The obtained results reveal that the introducing of 1,8-naphthalimideGly- and Caf- increase the cytotoxicity and antiproliferative activity of the peptides but not their selectivity. Only two compounds KLAKLAK-NH₂ and 1,8-naphthalimideGKnLAKnLAK-NH₂ show moderate activity against *Escherichia coli* K12 at low concentration of 20 μM.

Keywords: (KLAKLAK)₂-NH₂; anticancer peptides; 1,8-naphthalimide; caffeic acid; unnatural amino acids; antimicrobial activity; anticancer properties

1. Introduction

Most antimicrobial peptides contain 10 to 50 amino acids and are cationic with an amphipathic structure [1]. (KLAKLAK)₂ is a representative of this group of peptides, whose primary structure consists of 14 amino acids [2,3]. Theoretically the selectivity and mechanism of action of antimicrobial and anticancer peptides are similar. There are experimental data that these properties depend on availability of total negative charge of bacterial membrane and the tumor surface, due to high content of anionic molecules there, such as glycoconjugates, heparin sulfate, etc. [1,4]. On the other hand the normal mammalian cells contained many zwitterion structures in their phospholipid layer like

phosphatidylethanolamine, phosphatidylcholine, etc. which form a neutral total charge, making these cells less attractive for cationic antimicrobial peptides [5]. As a result, many peptides with proven antimicrobial activities have been tested and they showed anticancer effect [6–8]. Due to all mentioned above, antimicrobial peptides are of a large interest for scientific groups as possible alternative as anticancer compounds. Antimicrobial peptide (KLAKLAK)₂ is one of those peptides which shows antitumor properties, as on internalization it causes mitochondrial swelling and destruction of the mitochondrial membrane leading to apoptosis [9]. There are data in literature concerning different (KLAKLAK)₂ analogues and investigations on their anticancer potential [10]. Javadpour et al. described synthesis of peptides with the sequences: (KLAKKLA)_n, (KLAKLAK)_n (where $n = 1, 2, 3$), (KALKALK)₃, (KLGKKG)_n, and (KAAKAA)_n (where $n = 2, 3$) as the C-terminal amides. They realized several tests for cytotoxicity of those compounds and concluded that the peptides were much less lytic toward human erythrocytes than 3T3 cells at concentrations lower than 22 μM [2].

Introducing of unnatural amino acids in peptide structure regularly leads to changing, often increasing of main activity of the peptide. Thus many peptides with improved general activity are created such as anticancer analogues of somatostatin introduced in a medical practice octreotide and lanreotide [11–14], anticoagulant peptides [15–18], antiviral peptides [19–21], etc. Herein, we report the synthesis as well as cytotoxicity and antitumor studies of new shortened analogues of antimicrobial peptide (KLAKLAK)₂-NH₂ containing unnatural amino acids β -Ala and nor-Leu as well as their conjugates containing 1,8-naphthalimide and caffeic acid.

2. Results

A series of shortened analogues of (KLAKLAK)₂ as C-terminal amides with general structure Lys-X-Y-Lys-X-Y-Lys-NH₂, where X is Leu or nor-Leu (nL) and Y is Ala or β -Ala (β -A) were synthesized. In addition, their conjugates with general structure Z-Lys-X-Y-Lys-X-Y-Lys-NH₂, where X and Y are amino acids already mentioned above and Z is 1,8-naphthalimide-Gly or caffeic acid (Caf), were also obtained. (KLAKLAK)₂-NH₂ as a standard for further biological tests was also synthesized. All compounds were synthesized by SPPS, Fmoc/OtBu strategy. C-terminal amides were obtained by means of Rink-amide MBHA resin as solid-phase carrier. All condensation steps were realized with 3-[Bis(dimethylamino)methyl]methyl-3H-benzotriazol-1-oxide hexafluorophosphate (HBTU) or N,N'-Diisopropylcarbodiimide (DIC) as condensation reagents. Analytical data for newly synthesized peptides (Supplementary Materials) are summarized in Table 1.

Table 1. Structure and analytical data for newly synthesized compounds.

Abb	Peptide Structure	Molecular Formula	Mw _{exact}	[M + H] ⁺ Observed	[M + Na] ⁺ Observed	t _R (min)	M.p. [°C]	α_{546}^{20} [°] *	Chromatographic Purity (%)
Si1	(KLAKLAK) ₂ -NH ₂	C ₇₁ H ₁₃₅ N ₂₁ O ₁₅	1522.05	1523.30	-	3.53	118	-85	100.00
Si6	KLAKLAK-NH ₂	C ₃₅ H ₆₇ N ₁₁ O ₈	769.52	770.65	-	2.49	136	-33	100.00
Si7	1,8-naphthalimideG-KLAKLAK-NH ₂	C ₄₉ H ₇₄ N ₁₂ O ₁₁	1006.56	1007.70	-	3.44	89	-98	98.07
Si8	Caf-KLAKLAK-NH ₂	C ₄₅ H ₇₇ N ₁₁ O ₁₀	931.59	932.70	956.70	3.72	154	-35	82.37
Si3	KL β AKL β AK-NH ₂	C ₃₅ H ₆₇ N ₁₁ O ₈	769.52	770.70	-	2.48	123	-98	99.14
Si2	1,8-naphthalimideG-KL β AKL β AK-NH ₂	C ₄₉ H ₇₄ N ₁₂ O ₁₁	1006.56	1007.80	1029.75	1.48	98	-156	100.00
Si11	Caf-KL β AKL β AK-NH ₂	C ₄₅ H ₇₇ N ₁₁ O ₁₀	931.59	932.65	-	3.65	125	-23	82.17
Si13	KnLAKnLAK-NH ₂	C ₃₅ H ₆₇ N ₁₁ O ₈	769.52	770.80	-	1.25	93	-34	100.00
Si14	1,8-naphthalimideG-KnLAKnLAK-NH ₂	C ₄₉ H ₇₄ N ₁₂ O ₁₁	1006.56	1007.75	1029.75	3.42	a **	-12	87.48
Si15	Caf-KnLAKnLAK-NH ₂	C ₄₅ H ₇₇ N ₁₁ O ₁₀	931.59	932.75	-	1.33	92	-64	100.00

* methanol (c = 1); ** a-amorphous.

2.1. Cytotoxicity

The newly synthesized compounds were studied for cytotoxicity by standard method (3T3 NRU-test). The cells were incubated with the test substances at a concentration of 30 to 4000 μM for 24 h. The cytotoxicity expressed, in % relative to the negative control was determined. Dose-response dependence was observed for all substances. The obtained results are shown on Figure 1.




Figure 1. Cytotoxic effects of newly synthesized compounds. Dose-response curves for cytotoxicity assessment in BALB/3T3 cells.

The lowest toxicity was observed in **Si6** where no significant difference was observed compared to the negative control (untreated cells) and **Si13** where 20% cytotoxicity was observed at the highest concentration studied (4 mM). At a concentration of 250 μM , no cytotoxic effect was observed on the test substances. Based on dose–response curves, IC_{50} values were calculated by nonlinear regression analysis Table 2. According to IC_{50} values, the most toxic substance was **Si1** with $\text{IC}_{50} = 365.3 \pm 4.076 \mu\text{M}$ followed by **Si8** with $\text{IC}_{50} = 710.3 \pm 11.91 \mu\text{M}$ and **Si11** with $\text{IC}_{50} = 742.5 \pm 18.49 \mu\text{M}$. IC_{50} values for the other test substances are above 1000 μM , which is indicative of a low level of toxicity.

Table 2. Cytotoxic and antiproliferative potency of the studied substances expressed by IC_{50} values of the mean \pm SD.

Abb	Peptide Structure	IC_{50} of Mean \pm SD (μM)			
		Cytotoxicity	Antiproliferative Activity		
			BALB/3T3	MCF-10A	MCF-7
Si1	(KLAKLAK) ₂ -NH ₂	365.3 \pm 4.08	154 \pm 6.53	124.1 \pm 8.12	746.5 \pm 7.6
Si6	KLAKLAK-NH ₂	>4000	>2000	>2000	>2000
Si7	1,8-naphthalimideG-KLAKLAK-NH ₂	3422 \pm 51.26	1144 \pm 64.53	1195 \pm 131.5	>2000
Si8	Caf-KLAKLAK-NH ₂	710.3 \pm 11.91	135.6 \pm 7.09	128.6 \pm 8.03	514.3 \pm 26.82
Si3	KL β AKL β AK-NH ₂	2874 \pm 129.5	1469 \pm 103.8	176.3 \pm 4.66	>2000
Si2	1,8-naphthalimideG-KL β AKL β AK-NH ₂	1429 \pm 48.38	666 \pm 20.89	662.9 \pm 20.02	840 \pm 21.18
Si11	Caf-KL β AKL β AK-NH ₂	742.5 \pm 18.49	597.2 \pm 53.05	228.8 \pm 7.18	1087 \pm 70.71
Si13	KnLAKnLAK-NH ₂	>4000	>2000	1704 \pm 112	>2000
Si14	1,8-naphthalimideG-KnLAKnLAK-NH ₂	2893 \pm 61.38	630.8 \pm 51.16	593.3 \pm 60.3	1049 \pm 49.77
Si15	Caf-KnLAKnLAK-NH ₂	1514 \pm 12.16	146.8 \pm 7.96	140.3 \pm 7.12	346.3 \pm 7.91
Cisplatin *		>100	46.89 \pm 19.85	19.85 \pm 3.74	1.833 \pm 0.13

* positive control.

2.2. Antiproliferative Activity

The compounds were studied for antiproliferative activity by standard MTT dye reduction assay. Cell cultures from different cell line types (MCF-10A, MCF-7 and MDA-MB-231) were incubated with the test substances at a concentration of 15 to 2000 μM for 72 h. The antiproliferative activity expressed in % relative to the negative control was determined. The obtained results are shown on Figure 2. The IC_{50} values of the mean were calculated and presented in Table 2. MCF-10A is a reliable model for normal human mammary epithelial cells, which serves as a control in experiments to determine antitumor activity. The IC_{50} values, found in MCF-10A, are used to calculate a selective index (SI), which assesses the potential of a substance to be used as an antitumor agent. We used the following formula to calculate the selective index $\text{SI} = \text{IC}_{50}$ of MCF-10A / IC_{50} of tumor cells. The highest selective index with respect to MCF-7 is shown by the substances: **Si3** ($\text{SI} = 8.35$), **Si11** ($\text{SI} = 2.62$) and **Si1** ($\text{SI} = 1.24$). The calculated selective index in the positive control (Cisplatin) is 2.36. With respect to MDA-MB-231, $\text{SI} < 1$ was observed for any of the test substances. The widely used in clinical practice cytostatic Cisplatin (positive control) showed $\text{SI} = 25$.




Figure 2. Antiproliferative activity of newly synthesized compounds. Dose-response curves assessment in (a) Breast, non-tumorigenic epithelial cells (MCF-10A), (b) mammary gland type A adenocarcinoma (MCF-7) and (c) triple-negative breast cancer (MDA-MB-231).

2.3. Antibacterial Activity

Antibacterial properties of the obtained new peptides and their conjugates were tested against *E. coli* K12 407 strain. Antibacterial activity of tested compounds was proven through appear of free zone around the loaded disk-paper by means of agar-diffusion method (Figure 3).




Figure 3. Antibacterial activity measured by the agar disk-diffusion method against *E. coli* K12 407 as test microorganisms for: Si1 (A), Si6 (B), Si8 (C), Si13 (D), Si14 (E), Si15 (F).

The obtained results demonstrated clear zones free of microbial growth which means antibacterial effect around the samples Si1, Si6, Si8 and Si14 (Table 3). For the other compounds similar to Si13 and Si15 activity was found.

Table 3. Average inhibition zones size (mm) formed around compounds at concentration 20 μ M against *Escherichia coli* K12 407.

Abb	Peptide Structure	Average Value [mm] *
Si1	(KLAKLAK) ₂ -NH ₂ (control compound)	5 \pm 0.15
Si6	KLAKLAK-NH ₂	9.7 \pm 0.25
Si7	1,8-naphthalimideG-KLAKLAK-NH ₂	0
Si8	Caf-KLAKLAK-NH ₂	5 \pm 0.15
Si3	KL β AKL β AK-NH ₂	0
Si2	1,8-naphthalimideG-KL β AKL β AK-NH ₂	0
Si11	Caf-KL β AKL β AK-NH ₂	0
Si13	KnLAKnLAK-NH ₂	0
Si14	1,8-naphthalimideG-KnLAKnLAK-NH ₂	11.7 \pm 0.3
Si15	Caf-KnLAKnLAK-NH ₂	0

* Data are means of three replicates \pm SD.

3. Discussion

One of the main problems in medicinal therapy in general is intracellular transport of biologically active substance. In addition, especially concerning cancer therapy, the problem of tumor targeting also arises. Recently “targeted therapy” is one of the promising alternatives of chemotherapeutics in the fight against increasing cancer illness. Peptides can be specifically designed according to the needs and currently they are largely used as delivery systems for different purposes [22–25]. Nowadays, peptides are often used as conjugates able to transport and deliver different therapeutic molecules to specific targets in the organism, the process is well known as vectorization [26,27]. Moreover, the peptide can be conjugated to a cytotoxic drug to deliver it to the cancer cells expressing the corresponding peptide receptor [28] or attracting it to the specific features of tumor cells.

The investigation of Javadpour et al. reports that the 7-mer analogues of (KLAKLAK)₂ are devoid of tested biological activity [2]. Taking into account the fact that antimicrobial peptides have different mechanisms to penetrate cell membranes [29–31] we decided to conjugate 7-mer analogues of (KLAKLAK)₂ with second pharmacophore in order to test vectorizing potential of this peptide according to different cell lines. In addition, antitumor activity of obtained hybrid molecules was tested. Caffeic acid is well known and widely distributed in different natural products, with many proven positive effects and properties such as antimicrobial activity [32], antioxidant properties [33] and especially anticancer activity [34–39]. Due to the high similarity between the cell membrane in prokaryotes and the outer membrane in mitochondria, it is logical to conclude that the target of antibacterial peptides, administered to mammalian cells, is the outer mitochondrial membrane. When the peptide (KLAKLAK)₂-NH₂ and its derivatives interact with the outer mitochondrial membrane, they disrupt its structure and functionality. As a result, membrane permeability is increased and cytochrome C, ROS and other substances that activate apoptosis are released from the mitochondria. In addition, there is significant data in literature about the anticancer properties of 1,8-naphthalimide and its derivatives [40–44] are already used in medicinal practice [45,46]. Moreover, 1,8-naphthalimide molecule in our bioconjugates contributes for fluorescent properties. They can be used in a further investigation to evaluate cell penetration ability and intracellular distribution of newly synthesized compounds.

The substitutions of the natural amino acids Ala and Leu with their unnatural analogues β-alanine and nor-Leu were made, taking into account several important facts, supported by many results in the scientific literature:

The replacement of natural with unnatural amino acids makes resulting peptides difficult to be recognized as substrates by the enzymes responsible for their hydrolysis in the body. This often leads to increased hydrolytic stability and half-life of the obtained compounds in human plasma, which is important for their candidature as potential medical drugs;

A number of authors prove that single substitutions of natural with non-natural amino acids lead to improvement of specific properties or biological activity of newly synthesized compounds [11–21,47,48];

Beta-amino analog of Ala was selected to be introduced into the primary structure of aim peptides because it will lead to obtaining of more rigid incapable of conformational freedom structures. Such kinds of structures are more stable of hydrolysis in acid or basic condition [49]. On the other hand a lot of authors change natural amino acid Leu with nor-Leu because the second one is simultaneously a structural analogue of Ile and Met. Most recently, Chan et al. show that this kind of substitution in short peptides results in obtaining of structures with a higher tendency of self-organization, which support the interaction with the phospholipid membranes of the bacterial cell and enhance the biological effect of the peptide itself or a molecule carried by it [47,48].

All target peptides were synthesized using standard protocol of SPPS Fmoc/OtBu strategy on Rink-amide MBHA resin in order to assure final C-terminal amide, without any specific problems during the synthesis. If the step of condensation of some amino acid

needed to be repeated HBTU was replaced by DIC as a condensation agent. Not more than two repetitions of some steps were made. The first group of 3 compounds, abbreviated **Si6–8** (Table 1), includes 7-mer KLAKLAK and its conjugates with 1,8-naphthalimide and caffeic acid (Figure 4).




Figure 4. Chemical structures of second introduced in the molecule pharmacophore (A) naphthalimide and (B) caffeic acid.

We bonded 1,8-naphthalimide to the peptide chain using glycine as a linker in order to evaluate also the manner of bonding to the peptide chain on the biological activity. Thus, 1,8-naphthalimideglycine was synthesized with good yield and purity according to Marinov et al. [44].

The biological activity of the series is tested according to standard protocols for cytotoxicity (BALB/3T3 NRU-test) and antiproliferative activity (MTT dye reduction assay). **Si6** is practically non-toxic and does not show antiproliferative effects on the used cell lines at tested concentrations. The addition of 1,8-naphthalimide to KLAKLAK-NH₂ (1,8-naphthalimideG-KLAKLAK-NH₂ or **Si7**) resulted in a slight increase in cytotoxicity and antiproliferative effect in MCF-10A and MCF-7 cell lines. The addition of caffeic acid (**Si8**) resulted in a significant increase in cytotoxicity in BALB/c 3T3 cells (IC₅₀ decreased from > 4000 to 710.3 ± 11.91 μM). There was also more than ten-fold increase in antiproliferative activity (IC₅₀ from > 2000 to 135.6 ± 7.09, 128.6 ± 8.03 and 514.3 ± 26.82 for MCF-10A, MCF-7 and MDA-MB-231 respectively). The substances **Si6**, **Si7** and **Si8** do not show selectivity with respect to the studied tumor cell lines.

As it was already mentioned above replacement of natural with unnatural amino acids in the primary structure of some peptides often leads to increased activity. Taking into account this fact the second step of this investigation was to replace Ala with β-Ala and Leu with nor-Leu in the KLAKLAK sequence. Thus, a series of six compounds (**Si2,3,11,13,14,15**, Table 1) was synthesized including bioconjugates of newly synthesized peptides again with 1,8-naphthalimide and caffeic acid. Their biological activity was also tested against a panel of normal and tumor cell lines. Substitution of Ala with β-Ala in **Si3** resulted in a slight increase in cytotoxicity in BALB/c 3T3 cells (IC₅₀ = 2874 ± 129.5) and antiproliferative effect in MCF-10A cells (IC₅₀ = 1469 ± 103.8). In contrast **Si3** had a high antiproliferative effect (IC₅₀ = 176.3 ± 4.66) according to MCF-7. The calculated selective index for MCF-7 is significant (SI = IC₅₀ MCF-10A/IC₅₀ MCF-7 = 1469/176.3 = 8.33). Substitution of Leu with nor-Leu in **Si13** did not result in a significant change in biological activity in the cell lines used. The additional group (1,8-naphthalimideG) in **Si2** increases the biological activity but no significant SI is observed. Unlike **Si11**, where the group (Caf-) is added showed an increased antiproliferative effect and a significant selective index relative to MCF-7 cell line (SI = 2.62). **Si15** causes a significantly higher antiproliferative effect than **Si14**. This is probably due to the chemical group Caf- in **Si15**. No selectivity of the effect was observed in **Si14** and **Si15**.

MDA-MB-231 showed increased resistance to all test substances. This is probably due to the damaged mechanisms of apoptosis in these cells.

The obtained results presented in Table 3 show that only shortened analogue KLAKLAK-NH₂ and its conjugate with 1,8-naphthalimide containing unnatural amino acid nor-Leu (1,8-naphthalimideGKnLAKnLAK-NH₂) show moderate activity against the *Escherichia coli* K12 407 at 20 µM concentration. This result is in agreement with the results of Johnson et al. [50] who also observed antibacterial effect against strains *E. coli* of some tested analogues (KLAKLAK)₂-NH₂. The same authors suggested that antibacterial effect is due to cell membrane damage and followed by lysis accelerated by the peptide. Moreover, in accordance with Chan et al. substitution of Leu with nor-Leu could lead to obtaining of good candidates as vectorizing agents with better selectivity and improved antibacterial properties because of better interaction with specific phospholipid membranes [47,48]. Newly obtained analogues were also tested for antimicrobial activity against the model strain Gram-positive microorganisms *Bacillus subtilis* 3562 and the model strain fungi *Candida albicans* 74, but any activity was revealed.

4. Materials and Methods

4.1. Chemical Part

All specifically protected amino acids, Fmoc-Rink Amide MBHA Resin and other reagents and solvents for peptide synthesis were purchased from Iris Biotech (Marktredwitz, Germany). 1,8-naphthalic anhydride is from Sigma-Aldrich (Product of UK). Caffeic acid is from Alfa Aesar (Lancashire, UK).

The purity of newly synthesized compounds were monitored by means of Shimadzu LC MS/MS 8045 system (Shimadzu Corporation, Japan), column Agilent Poroshell 120, 100 mm × 4.6 mm, mobile phase rate 0.30 mL/min, column temperature 40 °C. The following gradient elution was developed: Mobile phase A: H₂O (10% AcCN; 0.1% HCOOH); Mobile phase B: AcCN (5% H₂O; 0.1% HCOOH). Gradient of mobile phase start with 80%A/20%B, passes through 5%A/95%B in 15 min and returns to 80%A/20%B in 22 min.

The MS detector is in SCAN regime/ESI+ mode of ionization with 3 L/min of the nebulizing gas flow, 10 L/min of the heating and drying gas flow, 350 °C interface temperature, 200 °C DL temperature and 400 °C heat block temperature.

The optical rotation was measured on automatic standard polarimeter Polamat A, Carl Zeis, Jena (Anton Paar Opto Tec GmbH, Seelze, Germany). Melting points were recorded on standard Kofler hot-stage microscope (Reichert, Austria).

For the synthesis of aimed peptides the conventional solid-phase peptide synthesis (SPPS) by means of Fmoc/OtBu strategy was used. Rink-amide MBHA resin was used as solid-phase carrier. HBTU (3-[Bis(dimethylamino)methyl]methyl-3H-benzotriazol-1-oxide hexafluorophosphate) or DIC (N,N'-Diisopropylcarbodiimide) were used as condensation reagents. Three-functional amino acid Lys was embedded as N^α-Fmoc-Lys(Boc)-OH. The coupling reactions were performed, using for amino acid/HBTU/HOBt/DIEA/resin a molar ratio 3/3/3/9/1 or amino acid/DIC/resin a molar ratio 3/3/1 and catalytic quantity of 4-N,N-dimethylaminopyridine. The N^α-Fmoc-group was deprotected on every step by treatment with 20% piperidine solution in N,N'-dimethylformamide (DMF). The coupling and deprotection reactions were checked by both the standard Kaiser and Chloranil test. The releasing of aimed peptides from the resin was done, using a mixture of 95% trifluoroacetic acid (TFA), 2.5% triisopropylsilane (TIS) and 2.5% water. The peptides were obtained as oils in TFA and further precipitated in cold dry diethyl ether. The peptide purity was monitored and their structure was proven on a Shimadzu LC MS/MS 8045 system using the condition described above. The optical rotation was measured in methanol at c = 1. The analytical data for the synthesized peptides are shown in Table 1.

1,8-naphthalimideglycine were synthesized according to Marinov et al. 2020 [44].

4.2. Biological Part

4.2.1. In Vitro Cytotoxicity Testing (3T3 NRU Test)

The cytotoxicity testing was performed as described by Borenfreund et al. [51] and the latest modification of the validated BALB/3T3 clone A31 Neutral Red Uptake Assay

(3T3 NRU test) [52] for cytotoxicity testing. BALB/3T3, clone A31 mouse embryo cells were grown as monolayer in 75 cm² tissue culture flasks in DMEM high-glucose (4.5 g/L), supplemented with 10% FBS and antibiotics (Sigma-Aldrich, Schnelldorf, Germany). Cultures were maintained at 37.5 °C in a humidified atmosphere under 5% CO₂. Cells were plated at a density of 1 × 10⁴ cells in 100 µL culture medium in each well of 96-well flat-bottomed microplates (Biologix, Lenexa, KS, USA) and allowed to adhere for 24 h. The test compounds, dissolved in DMSO and diluted in culture medium to concentration range 30 to 4000 µM were then added and the cell cultures were incubated for additional 24 h. A wide concentration range was applied (from 30 to 4000 µM) and the cells were incubated for additional 24 h. After treatment with Neutral Red medium, washing and treatment with the Ethanol/Acetic acid solution (NR Desorb), the absorption was measured on a TECAN microplate reader (TECAN, Grödig, Austria) at wavelength 540 nm.

4.2.2. In Vitro Antiproliferative Activity

The antiproliferative activity testing was performed on cell cultures from several human cell lines using the standard MTT-dye reduction assay, described by Mosmann [53]. The assay is based on the metabolism of the tetrazolium salt MTT to insoluble formazan by mitochondrial reductases. The formazan concentration can be determined spectrophotometrically. The measured absorption is an indicator of cell viability and metabolic activity. Cell lines: mammary gland type A adenocarcinoma ER+, PR+, HER2- (MCF-7), triple-negative breast cancer ER-, PR-, HER2- (MDA-MB-231) and breast, non-tumorigenic epithelial cell line (MCF-10A) were used in experiments. The cell lines were routinely grown as monolayers in 75 cm² tissue culture flasks under standard conditions (described above). Cells were plated at a density of 1 × 10³ cells in 100 µL in each well of 96-well flat-bottomed microplates and allowed to adhere for 24 h before treatment with test compounds. A concentration range from 15 to 2000 µM was applied for 72 h. The formazan absorption was registered using a microplate reader at λ = 540 nm. Antiproliferative activities were expressed as IC₅₀ values (concentrations required for 50% inhibition of cell growth), calculated using non-linear regression analysis (GraphPad Software, San Diego, CA, USA).

The statistical analysis included application of One-way ANOVA followed by Bonferroni's post hoc test. $p < 0.05$ was accepted as the lowest level of statistical significance. All results are presented as mean ± SD.

4.2.3. Antibacterial Assay

All newly synthesized derivatives of (KLAKLAK)₂-NH₂ at two concentrations 10 µM and 20 µM, were tested against facultative anaerobic gram-negative *Esherichia coli* NBIMCC K12 407. The strains were obtained from the culture collection of Bulgarian National Bank for Industrial Microorganisms and Cell Cultures (Sofia, Bulgaria) and were cultured in Luria-Bertani (LB) medium (Mumbai, India). The microbiological tests were performed using the agar diffusion method. The overnight pure cultures from tested strains were prepared in liquid LB-medium. A single colony was used for inoculating the liquid LB medium in order to maintain initial bacterial concentration of 1 × 10⁷ cfu/mL. 100 µL of bacterial suspensions were seeded on agar plates with solid LB-medium. After 30 min, sterile paper disks 6 mm in diameter were soaked with tested samples in amount of 6 µL and placed on the agar petri dishes surface. The plates were incubated for 24 h at 37 °C. The appeared inhibition zones and their size were measured. The sterile paper disks soaked with water was used as blank. Mean values were calculated by performing the experiments in triplicates.

5. Conclusions

The obtained results reveal that the introducing of 1,8-naphthalimideGly- and Caf- increase the cytotoxicity and antiproliferative activity of the peptides but not their selectivity.

A significant selective index is observed only for substances **Si3** and **Si11**. The common chemical structure of these substances is KL β AKL β AK-NH₂. Therefore, we believe that the component responsible for high biological activity and selectivity is the amino acid β -Ala in the structure of **Si3** and **Si11**. Due to the significantly higher biological activity of **Si1** ((KLAKLAK)₂-NH₂) compared to **Si6** (KLAKLAK-NH₂), we theoretically predict high antitumor activity and selectivity of the synthetic peptide (KL β AKL β AK)₂-NH₂. Only two of tested compounds **Si6** (KLAKLAK-NH₂) and **Si14** (1,8-naphthalimideGKnLAKnLAK-NH₂) show moderate activity against the model strain Gram-negative microorganisms *Escherichia coli* K12 at low concentration of 20 μ M.

Supplementary Materials: The following are available online.

Author Contributions: Synthesis and characterization of the aim compounds S.J. and D.D.; I.I. and I.S. cytotoxicity testing and antiproliferative activity tests; T.A., V.N. and N.G. antimicrobial activity tests and results description and discussion; E.N., D.D. and I.G. (Ivo Grabchev) design and work conception as well as methodology; HPLC-MS analysis, I.G. (Ivan Givechev); manuscript preparation and corrections D.D., I.I., N.G. and E.N. All authors have read and agreed to the published version of the manuscript.

Funding: The synthesis of aim compounds in this work are financially supported by the project 11873/Scientific Investigation Sector of University of Chemical Technology and Metallurgy. Antimicrobial activity tests are financed by project 12007/ Scientific Investigation Sector of University of Chemical Technology and Metallurgy. The work is realized as a part of National Program "EUROPEAN SCIENTIFIC NETWORKS" of Ministry of Science and Education of Bulgaria, project "Drug molecule" D01-278/05.10.2020.

Institutional Review Board Statement: This study does not involve any humans or animals.

Informed Consent Statement: Not applicable. This study does not involve any humans or animals. The MCF-7: MDA-MB-231, MCF-10A and BALB/3T3 clone A31 cell lines were obtained from American Type Cultures Collection (ATCC, Manassas, VA, USA).

Data Availability Statement: Data is contained within the article or supplementary material.

Acknowledgments: Authors would like to thank to Testing Center Global Test Ltd. for using of specific HPLC/MS/MS equipment.

Conflicts of Interest: All authors declare no conflict of interest.

Sample Availability: Limited amounts of the compounds are available from the authors of UCTM.

References

1. Deslouches, B.; Peter, Y. Antimicrobial peptides with selective antitumor mechanisms: Prospect for anticancer applications. *Oncotarget* **2017**, *8*, 46635–46651. [[CrossRef](#)]
2. Javadpour, M.; Juban, M.; Lo, W.; Bishop, S.; Alberti, J.; Cowell, S.; Becker, C.; McLaughlin, M. De novo antimicrobial peptides with low mammalian cell toxicity. *J. Med. Chem.* **1996**, *39*, 3107–3113. [[CrossRef](#)]
3. Mai, J.; Mi, Z.; Kim, S.; Ng, B.; Robbins, P. A proapoptotic peptide for the treatment of solid tumors. *Cancer Res.* **2001**, *61*, 7709–7712.
4. Oelkrug, C.; Hartke, M.; Schubert, A. Mode of Action of Anticancer Peptides (ACPs) from Amphibian Origin. *Anticancer Res.* **2015**, *35*, 635–644. [[PubMed](#)]
5. Schweizer, F. Cationic amphiphilic peptides with cancer-selective toxicity. *Eur. J. Pharmacol.* **2009**, *625*, 190–194. [[CrossRef](#)]
6. Mader, J.S.; Hoskin, D.W. Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. *Expert Opin. Investig. Drugs* **2006**, *15*, 933–946. [[CrossRef](#)] [[PubMed](#)]
7. Mistry, N.; Drobni, P.; Näslund, J.; Sunkari, V.G.; Jenssen, H.; Evander, M. The anti-papillomavirus activity of human and bovine lactoferricin. *Antivir. Res.* **2007**, *75*, 258–265. [[CrossRef](#)] [[PubMed](#)]
8. Marqus, S.; Pirogova, E.; Piva, T. Evaluation of the use of therapeutic peptides for cancer treatment. *J. Biomed. Sci.* **2017**, *24*, 21. [[CrossRef](#)]
9. Thundimadathil, J. Cancer Treatment Using Peptides: Current Therapies and Future Prospects. *J. Amino Acids* **2012**, *2012*, 967347. [[CrossRef](#)]
10. Ellerby, H.M.; Arap, W.; Ellerby, L.M.; Kain, R.; Andrusiak, R.; Del Rio, G.; Krajewski, S.; Lombardo, C.R.; Rao, R.; Ruoslahti, E.; et al. Anti-cancer activity of targeted pro-apoptotic peptides. *Nat. Med.* **1999**, *5*, 1032–1038. [[CrossRef](#)]
11. Pollak, M. The potential role of somatostatin analogues in breast cancer treatment. *Yale J. Biol. Med.* **1997**, *70*, 535–539.

12. Pollak, M.N.; Shally, A.V. Mechanisms of antineoplastic action of somatostatin analogs. *Proc. Soc. Exp. Biol. Med.* **1998**, *217*, 143–152. [[CrossRef](#)] [[PubMed](#)]
13. Appetecchia, M.; Baldelli, R. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. *J. Exp. Clin. Cancer Res.* **2010**, *29*, 19. [[CrossRef](#)] [[PubMed](#)]
14. Strosberg, J.; Kvols, L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. *World J. Gastroenterol.* **2010**, *16*, 2963–2970. [[CrossRef](#)]
15. Angliker, H.; Stone, S.; Shaw, E. Thrombin inhibitors based on peptidyl halomethanes with a long peptide sequence. In *Peptides*; Springer: Berlin/Heidelberg, Germany, 1990; pp. 772–773.
16. Kettner, C.; Mersinger, L.; Knabb, R. The selective inhibition of thrombin by peptides of boroarginine. *J. Biol. Chem.* **1990**, *265*, 18289–18297. [[CrossRef](#)]
17. Cheng, L.; Goodwin, C.; Scully, M.; Kakkar, V.V.; Claeson, G. Substrate-related phosphonopeptides, a new class of thrombin inhibitors. *Tetrahedron Lett.* **1991**, *32*, 7333–7336. [[CrossRef](#)]
18. Rupin, A.; Mennecier, P.; Lila, C.; de Nanteuil, G.; Verbeuren, T.J. Selection of S18326 as a new potential and selective boronic acid direct thrombin inhibitor. *Thromb. Haemost.* **1997**, *78*, 1221–1227. [[PubMed](#)]
19. Chayrov, R.; Stylos, E.; Chatziathanasiadou, M.; Chuchkov, K.; Tencheva, A.; Kostagianni, A.; Milkova, T.; Angelova, A.; Galabov, A.; Shishkov, S.; et al. Tailoring acyclovir prodrugs with enhanced antiviral activity: Rational design, synthesis, human plasma stability and in vitro evaluation. *Amino Acids* **2018**, *50*, 1131–1143. [[CrossRef](#)]
20. Chuchkov, K.; Nakova, C.; Mukova, L.; Galabov, A.; Stankova, I. New derivatives of oseltamivir with bile acids. *Chemistry* **2015**, *24*, 355–362.
21. Chayrov, R.; Mukova, L.; Galabov, A.; Mitrev, Y.; Stankova, I. Amantadine analogues—Synthesis and biological activity. *Bulg. Chem. Commun.* **2017**, *49*, 61–63.
22. Snyder, E.L.; Dowdy, S.F. Cell Penetrating Peptides in Drug Delivery. *Pharm. Res.* **2004**, *21*, 389–393. [[CrossRef](#)]
23. Tréhin, R.; Merkle, H.P. Chances and pitfalls of cell penetrating peptides for cellular drug delivery. *Eur. J. Pharm. Biopharm.* **2004**, *58*, 209–223. [[CrossRef](#)]
24. Vives, E. Present and future of cell-penetrating peptide mediated delivery systems: “Is the Trojan horse too wild to go only to Troy?”. *J. Control. Release* **2005**, *109*, 77–85. [[CrossRef](#)] [[PubMed](#)]
25. Foerg, C.; Merkle, H.P. On the biomedical promise of cell penetrating peptides: Limits versus prospects. *J. Pharm. Sci.* **2008**, *97*, 144–162. [[CrossRef](#)]
26. Morris, M.C.; Deshayes, F.; Simeoni, F.; Adrian-Herrada, G.; Heitz, F.; Divita, G. A noncovalent peptide-based strategy for peptide and short interfering RNA delivery. In *Cell Penetrating Peptides*; Langel, Ü., Ed.; CRC Press: Boca Raton, FL, USA, 2007; pp. 387–408.
27. Crombez, L.; Gudrun, A.; Konate, K.; Nguyen, Q.N.; McMaster, G.; Brasseur, R.; Heitz, F.; Divita, G. A New Potent Secondary Amphipathic Cell-penetrating Peptide for siRNA Delivery Into Mammalian Cells. *Mol. Ther.* **2009**, *17*, 95–107. [[CrossRef](#)]
28. Shikolenko, I.N.; Alexeyev, M.F.; LeDoux, S.P.; Wilaon, G.L. Tat-mediated protein transduction and targeted delivery of fusion proteins into mitochondria of breast cancer cells. *DNA Repair* **2005**, *4*, 511–518. [[CrossRef](#)]
29. Moghaddam, M.M.; Aghamollaei, H.; Kooshki, H.; Barjini, K.A.; Mirnejad, R.; Choopani, A. The development of antimicrobial peptides as an approach to prevention of antibiotic resistance. *Rev. Med. Microbiol.* **2015**, *26*, 98–110. [[CrossRef](#)]
30. Gestin, M.; Dowaidar, M.; Langel, Ü. Uptake Mechanism of Cell-Penetrating Peptides. In *Peptides and Peptide-Based Biomaterials and Their Biomedical Applications. Advances in Experimental Medicine and Biology*; Sunna, A., Care, A., Bergquist, P., Eds.; Springer: Cham, Switzerland, 2017.
31. Roudi, R.; Syn, N.L.; Roudbary, M. Antimicrobial Peptides as Biologic and immunotherapeutic Agents against Cancer: A Comprehensive Overview. *Front. Immunol.* **2017**, *8*, 1320. [[CrossRef](#)] [[PubMed](#)]
32. Guzman, J.D. Natural cinnamic acids, synthetic derivatives and hybrids with antimicrobial activity. *Molecules* **2014**, *19*, 19292–19349. [[CrossRef](#)]
33. Maurya, D.K.; Devasagayam, T.P. Antioxidant and prooxidant nature of hydroxycinnamic acid derivatives ferulic and caffeic acids. *Food Chem. Toxicol.* **2010**, *48*, 3369–3373. [[CrossRef](#)] [[PubMed](#)]
34. Chung, T.-W.; Moon, S.-K.; Chang, Y.-C.; Ko, J.-H.; Lee, Y.-C.; Cho, G.; Kim, S.-H.; Kim, J.-G.; Kim, C.-H. Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: Complete regression of hepatoma growth and metastasis by dualmechanism. *FASEB J.* **2004**, *18*, 1670–1681. [[CrossRef](#)]
35. Chang, W.-C.; Hsieh, C.-H.; Hsiao, M.-W.; Lin, W.-C.; Hung, Y.-C.; Ye, J.-C. Caffeic acid induces apoptosis in human cervical cancer cells through the mitochondrial pathway. *Taiwan J. Obstet. Gynecol.* **2010**, *49*, 419–424. [[CrossRef](#)]
36. Prasad, N.R.; Karthikeyan, A.; Karthikeyan, S.; Reddy, B.V. Inhibitory effect of caffeic acid on cancer cell proliferation by oxidative mechanism in human HT-1080 fibrosarcoma cell line. *Mol. Cell. Biochem.* **2011**, *349*, 11–19. [[CrossRef](#)] [[PubMed](#)]
37. Murad, L.D.; Soares, N.D.C.P.; Brand, C.; Monteiro, M.C.; Teodoro, A.J. Effects of caffeic and 5-caffeoylquinic acids on cell viability and cellular uptake in human colon adenocarcinoma cells. *Nutr. Cancer* **2015**, *67*, 532–542. [[CrossRef](#)]
38. Rosendahl, A.H.; Perks, C.M.; Zeng, L.; Markkula, A.; Simonsson, M.; Rose, C.; Ingvar, C.; Holly, J.M.P.; Jernström, H. Caffeine and caffeic acid inhibit growth and modify estrogen receptor and insulin-like growth factor I receptor levels in human breast cancer. *Clin. Cancer Res.* **2015**, *21*, 1877–1887. [[CrossRef](#)]

39. Ignatova, M.G.; Manolova, N.I.; Rashkov, I.B.; Markova, N.D.; Toshkova, R.A.; Georgieva, A.K.; Nikolova, E.B. Poly(3-hydroxybutyrate)/caffeic acid electrospun fibrous materials coated with polyelectrolyte complex and their antibacterial activity and in vitro antitumor effect against HeLa cells. *Mater. Sci. Eng. C* **2016**, *65*, 379–392. [[CrossRef](#)] [[PubMed](#)]
40. Braña, M.F.; Ramos, A. Naphthalimides as anticancer agents: Synthesis and biological activity. *Anti-Cancer Agents Med. Chem.* **2001**, *1*, 237–255. [[CrossRef](#)]
41. Banerjee, S.; Veale, E.B.; Phelan, C.M.; Murphy, S.A.; Tocci, G.M.; Gillespie, L.J.; Frimannsson, D.O.; Kelly, J.M.; Gunnaugsson, T. Recent advances in the development of 1,8-naphthalimide based DNA targeting binders, anticancer and fluorescent cellular imaging agents. *Chem. Soc. Rev.* **2013**, *42*, 1601–1618. [[CrossRef](#)]
42. Kamal, A.; Bolla, N.R.; Srikanth, P.S.; Srivastava, A.K. Naphthalimide derivatives with therapeutic characteristics: A patent review. *Expert Opin. Ther. Pat.* **2013**, *23*, 299–317. [[CrossRef](#)]
43. Wang, K.-R.; Qian, F.; Wang, X.-M.; Tan, G.-H.; Rong, R.-X.; Cao, Z.-R.; Chen, H.; Zhang, P.-Z.; Li, X.-L. Cytotoxic activity and DNA binding of naphthalimide derivatives with amino acid and dichloroacetamide functionalizations. *Chin. Chem. Lett.* **2014**, *25*, 1087–1093. [[CrossRef](#)]
44. Marinov, M.N.; Naydenova, E.D.; Momekov, G.T.; Prodanova, R.Y.; Markova, N.V.; Voynikov, Y.T.; Stoyanov, N.M. Synthesis, Characterization, Quantum-Chemical Calculations and Cytotoxic Activity of 1,8-Naphthalimide Derivatives with Non-Protein Amino Acids. *Anti-Cancer Agents Med. Chem.* **2019**, *19*, 1276–1284. [[CrossRef](#)] [[PubMed](#)]
45. Braña, M.F.; Castellano, J.M.; Jiménez, A.; Lombart, A.; Rabadan, F.P.; Roldán, M.; Roldán, C.; Santos, A.; Vázquez, D. Synthesis, cytostatic activity and mode of action of a new series of imide derivatives of 3-nitro-11 α naphthalic acid. *Curr. Chemother.* **1978**, *2*, 1216–1217.
46. Braña, M.F.; Castellano, J.M.; Roldán, C.M.; Santos, A.; Vázquez, D.; Jiménez, A. Synthesis and mode(s) of action of a new series of imide derivatives of 3-nitro-1,8 naphthalic acid. *Cancer Chemother. Pharmacol.* **1980**, *4*, 61–66. [[CrossRef](#)]
47. Chan, K.H.; Xue, B.; Robinson, R.C.; Hauser, C.A.E. Systematic single moiety variations of ultrashort peptides produce profound effects on self-assembly, nanostructure formation, hydrogelation, and phase transition. *Sci. Rep.* **2017**, *7*, 12897. [[CrossRef](#)]
48. Chan, K.H.; Lee, W.H.; Ni, M.; Loo, Y.; Hauser, C.A.E. C-Terminal residue of ultrashort peptides impacts on molecular self-assembly, hydrogelation, and interaction with small-molecule drugs. *Sci. Rep.* **2018**, *8*, 17127. [[CrossRef](#)] [[PubMed](#)]
49. Cabrele, C.; Martinek, T.A.; Reiser, O.; Berlicki, Ł. Peptides Containing β -Amino Acid Patterns: Challenges and Successes in Medicinal Chemistry. *J. Med. Chem.* **2014**, *57*, 9718–9739. [[CrossRef](#)]
50. Johnson, G.; Ellis, E.; Kim, H.; Muthukrishnan, N.; Snavely, T.; Pellois, J.-P. Photoinduced Membrane Damage of *E. coli* and *S. aureus* by the Photosensitizer-ntimicrobial Peptide Conjugate Eosin-(KLAKLAK)₂. *PLoS ONE* **2014**, *9*, e91220.
51. Borenfreund, E.; Puerner, J.A. Toxicity determined in vitro by morphological alterations and Neutral Red absorption. *Toxicol. Lett.* **1985**, *24*, 119–124. [[CrossRef](#)]
52. Spielmann, H.; Balls, M.; Dupuis, J.; Pape, W.J.W.; Pechovitch, G.; de Silva, O. The international EU/COLIPA in vitro phototoxicity validation study: Results of Phase II (blind trial). Part I: The 3T3 NRU phototoxicity test. *Toxicol. In Vitro* **1998**, *12*, 305–327. [[CrossRef](#)]
53. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J. Immunol. Methods* **1983**, *65*, 55–63. [[CrossRef](#)]